Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First-In-Human Dose-Escalation Study of Fianlimab, an Anti-Lymphocyte Activation Gene-3 Antibody, with Cemiplimab in patients with advanced malignancies.
Lakhani NJ, Papadopoulos KP, Johnson ML, Park H, Wang D, Yap TA, Dowlati A, Maki RG, Ulahannan S, Lynce F, Kelly K, Williamson S, Malhotra J, Chen S, Gonzalez Ortiz A, Jankovic V, Paccaly A, Masinde S, Mani J, Lowy I, Gullo G, Sims T, Kroog G. Lakhani NJ, et al. Among authors: jankovic v. Clin Cancer Res. 2024 Oct 18. doi: 10.1158/1078-0432.CCR-23-3883. Online ahead of print. Clin Cancer Res. 2024. PMID: 39422598
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.
Hamid O, Lewis KD, Weise A, McKean M, Papadopoulos KP, Crown J, Kim TM, Lee DH, Thomas SS, Mehnert J, Kaczmar J, Lakhani NJ, Kim KB, Middleton MR, Rabinowits G, Spira AI, Yushak M, Mehmi I, Fang F, Chen S, Mani J, Jankovic V, Wang F, Fiaschi N, Brennan L, Paccaly A, Masinde S, Salvati M, Fury MG, Kroog G, Lowy I, Gullo G. Hamid O, et al. Among authors: jankovic v. J Clin Oncol. 2024 Aug 20;42(24):2928-2938. doi: 10.1200/JCO.23.02172. Epub 2024 Jun 20. J Clin Oncol. 2024. PMID: 38900987 Free PMC article. Clinical Trial.
Safety and Immune Responses Following Anti-PD-1 Monoclonal Antibody Infusions in Healthy Persons With Human Immunodeficiency Virus on Antiretroviral Therapy.
Gay CL, Bosch RJ, McKhann A, Cha R, Morse GD, Wimbish CL, Campbell DM, Moseley KF, Hendrickx S, Messer M, Benson CA, Overton ET, Paccaly A, Jankovic V, Miller E, Tressler R, Li JZ, Kuritzkes DR, Macatangay BJC, Eron JJ, Hardy WD; A5370 Team. Gay CL, et al. Among authors: jankovic v. Open Forum Infect Dis. 2024 Jan 11;11(3):ofad694. doi: 10.1093/ofid/ofad694. eCollection 2024 Mar. Open Forum Infect Dis. 2024. PMID: 38449916 Free PMC article. Clinical Trial.
CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models.
Wei J, Montalvo-Ortiz W, Yu L, Krasco A, Olson K, Rizvi S, Fiaschi N, Coetzee S, Wang F, Ullman E, Ahmed HS, Herlihy E, Lee K, Havel L, Potocky T, Ebstein S, Frleta D, Khatri A, Godin S, Hamon S, Brouwer-Visser J, Gorenc T, MacDonald D, Hermann A, Chaudhry A, Sirulnik A, Olson W, Lin J, Thurston G, Lowy I, Murphy AJ, Smith E, Jankovic V, Sleeman MA, Skokos D. Wei J, et al. Among authors: jankovic v. Sci Transl Med. 2022 Nov 9;14(670):eabn1082. doi: 10.1126/scitranslmed.abn1082. Epub 2022 Nov 9. Sci Transl Med. 2022. PMID: 36350988
Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Brouwer-Visser J, Fiaschi N, Deering RP, Cygan KJ, Scott D, Jeong S, Boucher L, Gupta NT, Gupta S, Adler C, Topp MS, Bannerji R, Duell J, Advani RH, Flink DM, Chaudhry A, Thurston G, Ambati SR, Jankovic V. Brouwer-Visser J, et al. Among authors: jankovic v. J Immunother Cancer. 2024 Mar 21;12(3):e008338. doi: 10.1136/jitc-2023-008338. J Immunother Cancer. 2024. PMID: 38519055 Free PMC article.
Cancer cell-derived type I interferons instruct tumor monocyte polarization.
Kwart D, He J, Srivatsan S, Lett C, Golubov J, Oswald EM, Poon P, Ye X, Waite J, Zaretsky AG, Haxhinasto S, Au-Yeung E, Gupta NT, Chiu J, Adler C, Cherravuru S, Malahias E, Negron N, Lanza K, Coppola A, Ni M, Song H, Wei Y, Atwal GS, Macdonald L, Oristian NS, Poueymirou W, Jankovic V, Fury M, Lowy I, Murphy AJ, Sleeman MA, Wang B, Skokos D. Kwart D, et al. Among authors: jankovic v. Cell Rep. 2022 Dec 6;41(10):111769. doi: 10.1016/j.celrep.2022.111769. Cell Rep. 2022. PMID: 36476866 Free article.
Phylogenomic and genomic analysis reveals unique and shared genetic signatures of Mycobacterium kansasii complex species.
Machado E, Vasconcellos S, Gomes L, Catanho M, Ramos J, de Carvalho L, Goldenberg T, Redner P, Caldas P, Campos C, Dalcolmo M, Lourenço MC, Lasunskaia E, Mussi V, Spinassé L, Vinhas S, Rigouts L, Cogneau S, de Rijk P, Utpatel C, Kaustova J, van der Laan T, de Neeling H, Rastogi N, Levina K, Kütt M, Mokrousov I, Zhuravlev V, Makhado N, Žolnir-Dovč M, Jankovic V, de Waard J, Sisco MC, van Soolingen D, Niemann S, de Jong BC, Meehan CJ, Suffys P. Machado E, et al. Among authors: jankovic v. Microb Genom. 2024 Jul;10(7):001266. doi: 10.1099/mgen.0.001266. Microb Genom. 2024. PMID: 39016539 Free PMC article.
Reccurent guillain barré syndrome after COVID-19.
Miletic Drakulic SD, Lazarevic SR, Miloradovic IP, Jankovic VS. Miletic Drakulic SD, et al. Among authors: jankovic vs. Neurosciences (Riyadh). 2023 Oct;28(4):273-276. doi: 10.17712/nsj.2023.4.20230012. Neurosciences (Riyadh). 2023. PMID: 37844949 Free PMC article.
97 results